B
Bangkok Lab and Cosmetic PCL
SET:BLC
Bangkok Lab and Cosmetic PCL
SET:BLC
Price:
3.82
THB
-0.52%
Market Closed
Market Cap:
฿2.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
TH |
|
E
|
Electricity Generating PCL
SET:EGCO
|
TH |
|
Xlife Sciences AG
SIX:XLS
|
CH |
|
V
|
VerticalScope Holdings Inc
TSX:FORA
|
CA |
|
Csam Health Group AS
OSE:CSAM
|
NO |
|
Seagate Technology Holdings PLC
NASDAQ:STX
|
IE |
|
Westlake Corp
NYSE:WLK
|
US |
|
S
|
Starflex PCL
SET:SFLEX
|
TH |
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
US |
|
HLS Therapeutics Inc
TSX:HLS
|
CA |
|
P
|
Propel Global Bhd
KLSE:PGB
|
MY |
|
Hexo Corp
TSX:HEXO
|
CA |
|
Ops Ecom SpA
MIL:OEC
|
IT |
|
Lufax Holding Ltd
NYSE:LU
|
CN |
Multiples-Based Value
The Multiples-Based Value of one BLC stock under the Base Case scenario is hidden THB. Compared to the current market price of 3.82 THB, Bangkok Lab and Cosmetic PCL is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BLC Multiples-Based Value
LOCKED
Multiples Across Competitors
BLC Competitors Multiples
Bangkok Lab and Cosmetic PCL Competitors
Bangkok Lab and Cosmetic PCL Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| TH |
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
2.3B THB | 1.4 | 13.2 | 8.2 | 10.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
